Next Article in Journal
Effects of Platycodon grandiflorum on Gut Microbiome and Immune System of Immunosuppressed Mouse
Next Article in Special Issue
Pharmacokinetic, Metabolomic, and Stability Assessment of Ganoderic Acid H Based Triterpenoid Enriched Fraction of Ganoderma lucidum P. Karst
Previous Article in Journal
Predicting Hair Cortisol and Cortisone Concentration in Postpartum Women through Repeated Measurements of Perceived Stress
Previous Article in Special Issue
Dereplication, Annotation, and Characterization of 74 Potential Antimicrobial Metabolites from Penicillium Sclerotiorum Using t-SNE Molecular Networks
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Metabolites
Volume 11
Issue 12
10.3390/metabo11120816
metabolites-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Chemical Composition of the Red Sea Green Algae Ulva lactuca: Isolation and In Silico Studies of New Anti-COVID-19 Ceramides

by
Enas E. Eltamany
1,†,
Sameh S. Elhady
2,†,
Marwa S. Goda
1,
Omar M. Aly
3,
Eman S. Habib
1,
Amany K. Ibrahim
1,
Hashim A. Hassanean
1,
Usama Ramadan Abdelmohsen
4,5,
Martin K. Safo
6 and
Safwat A. Ahmed
1,*
1
Department of Pharmacognosy, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt
2
Department of Natural Products, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia
3
Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, 61519 Minia, Egypt
4
Department of Pharmacognosy, Faculty of Pharmacy, Minia University, Minia 61519, Egypt
5
Department of Pharmacognosy, Faculty of Pharmacy, Deraya University, New Minia 61111, Egypt
6
Department of Medicinal Chemistry, and Institute for Structural Biology, Drug Discovery and Development, School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23219, USA
*
Author to whom correspondence should be addressed.
†
These authors equally contributed to this work.
Metabolites 2021, 11(12), 816; https://doi.org/10.3390/metabo11120816
Submission received: 20 October 2021 / Revised: 27 November 2021 / Accepted: 28 November 2021 / Published: 29 November 2021
(This article belongs to the Special Issue Metabolomics Analysis of Natural Products)
Browse Figures
Versions Notes

Abstract

:
Coronavirus disease 2019 (COVID-19) is the disease caused by the virus SARS-CoV-2 responsible for the ongoing pandemic which has claimed the lives of millions of people. This has prompted the scientific research community to act to find treatments against the SARS-CoV-2 virus that include safe antiviral medicinal compounds. The edible green algae U. lactuca. is known to exhibit diverse biological activities such as anti-influenza virus, anti-Japanese encephalitis virus, immunomodulatory, anticoagulant, antioxidant and antibacterial activities. Herein, four new ceramides in addition to two known ones were isolated from Ulva lactuca. The isolated ceramides, including Cer-1, Cer-2, Cer-3, Cer-4, Cer-5 and Cer-6 showed promising antiviral activity against SARS-CoV-2 when investigated using in silico approaches by preventing its attachment to human cells and/or inhibiting its viral replication. Cer-4 and Cer-5 were the most effective in inhibiting the human angiotensin converting enzyme (hACE)–spike protein complex which is essential for the virus to enter the human host. In addition to this, Cer-4 also showed an inhibition of the SARS-CoV-2 protease (Mpro) that is responsible for its viral replication and transcription. In this study, we also used liquid chromatography coupled to electrospray ionization high-resolution mass spectroscopy (LC-ESI-HRMS) to identify several metabolites of U. lactuca, including metabolites such as fatty acids, their glyceride derivatives, terpenoids, sterols and oxysterols from the organic extract. Some of these metabolites also possessed promising antiviral activity, as previously reported.

Graphical Abstract

1. Introduction

Coronaviruses (CoVs) are positive RNA genome viruses belonging to the Coronaviridae family of the Nidovirales order, which is divided into four genera (A, B, C, D). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) belongs to the B genus [1]. In March 2020, the World Health Organization (WHO) declared that the coronavirus disease 2019 (COVID-19) outbreak was a pandemic. A novel coronavirus is a new strain that has not been previously identified in humans. CoVs have at least four structural proteins: namely spike protein, cover protein, membrane protein and nucleocapsid protein. The spike protein promotes host attachment and viral cell membrane fusion during virus infection [1]. Nowadays, scientific research is oriented towards the discovery of safe therapeutic agents that would cure COVID-19 or reduce its prevalence. Potential anti-coronavirus treatments can be divided into two main categories: one operating on the human immune system or human cells, and the other on the coronavirus itself [2]. Viruses often bind to receptor proteins on the surfaces of cells to enter human cells, for example, by linking with the human angiotensin-converting enzyme 2 (hACE2) receptor [3,4,5]. Protein–protein docking showed that SARS-CoV-2 spike proteins have a strong affinity for hACE2 [6]. Therefore, determining safe and natural compounds that inhibit COVID-19 spike protein attachment to hACE2 would potentially lead to better treatment against this disease.
Genus Ulva belongs to the family Ulvaceae which is comprised of cosmopolitan and abundant green macroalgae (approximately 100 species) that inhabit freshwater as well as saline shallow environments [7,8,9]. This algal genus is used as a source of traditional food in many Asian countries. In addition, several biological investigations revealed that Ulva can be of potential interest for the development of novel drugs and functional foods [9,10]. Ulva spp. were proved to possess diverse pharmacological effects that are ascribed to their chemical constituents which are mainly fatty acids, ceramides, terpenes, phenolics [10] and most importantly, sulphated polysaccharides known as ulvans. These sulfated polysaccharides were extracted from different Ulva species and displayed significant bioactivities in both in vitro and in vivo studies such as immune modulatory, anti-inflammatory, anticoagulant, antihyperlipidemic, cytotoxicity and antiviral potential against a broad range of enveloped and non-enveloped viruses [11]
U. lactuca is an edible green seaweed often known as sea lettuce. It grows on reef flats and rocky shores in the lower intertidal zone affected by waves [12,13,14]. Phytochemical investigations of U. lactuca resulted in the isolation of several bioactive phytoconstituents such as (+)-Epiloliolide, a carotenoid derivative which exhibited an apoptotic effect via the regulation of the p53 gene [13], an anti-inflammatory pyrone analogue of benzochromene named ulvapyrone [15] and 3-O-β-D glucopyranosyl-stigmasta-5,25-dien which has displayed antibacterial and antifungal effects [16]. In addition, palmitic acid, isofucosterol, hydrocarbons and norterpenes were also reported in U. lactuca [17,18]. It is noteworthy that the crude extracts of different Ulva species (including U. lactuca) exhibited significant antiviral activity against various DNA and RNA viruses [19,20,21,22,23,24,25,26,27,28,29]. Furthermore, the antiviral effect of ceramides and their derivatives was proven [30,31,32,33]. These findings and observations make U. lactuca a potential natural remedy for curing respiratory viral infections. Therefore, the purpose of this study was to isolate bioactive natural compounds from U. lactuca with promising antiviral activity against SARS-CoV-2 in addition to the rapid identification of its metabolites using liquid chromatography coupled to electrospray ionization high-resolution mass spectroscopy (LC-ESI-HRMS) technique.

2. Results and Discussion

2.1. Metabolic Profiling

The metabolic profiling of the crude extract of U. lactuca, performed using LC-ESI-HRMS (Figures S1 and S2), showed the presence of a panel of diverse metabolites such as fatty acids, glycerides, sterols and oxysterols, ceramides, terpenoids, carbohydrates and amino acids (Table 1). These metabolites were detected by comparing their exact masses, with those recorded in databases, e.g., the Dictionary of Natural Products (DNP) and Metabolite and Chemical Entity (METLIN). Mass accuracy was determined by ((detected mass–expected mass)/expected mass) × 106 and expressed in parts per million (ppm) error [34]. Previous assessment of the antiviral activity of various fatty acids revealed that medium-chain saturated and long-chain unsaturated fatty acids were highly active against enveloped viruses such as Vesicular stomatitis virus and Herpes simplex virus. Additionally, the monoglycerides of these fatty acids showed high antiviral activity at a concentration 10 times lower than that of free fatty acids. It was suggested that these antiviral fatty acids were able to disturb the viral envelope, causing leakage or a complete disintegration of the envelope and consequently the viral particles [35]. Moreover, some sterols have been shown to possess viral inhibition activity such as stigmasterol, which was effective against tobamoviruses with a virus inhibitory activity of 64% [36]. Ingallinella and coworkers [37] reported that the addition of a cholesterol group to enfuvirtide, Human Immune Virus -1 (HIV-1) peptide fusion inhibitor, potentiates its antiviral activity with IC90 values 300-fold lower than that of enfuvirtide alone. Oxysterols are cholesterol derivatives that contain an additional hydroxyl, epoxide or ketone group in the sterol nucleus and/or in the side chain, which have demonstrated antiviral activity by the inhibition of the viral replication of viruses with an external lipid membrane [38]. It is worth mentioning that oxysterols with a hydroxyl group at C-25 may inhibit the replication of hepatitis C virus, while oxysterol containing a hydroxyl group in its side chain, namely 24- hydroxycholesterol, may inhibit the murine cytomegalovirus and Herpes simplex virus type 1. With the additional oxygenation or hydroxylation of ring B, 7-ketone, 7α-OH and 7β-OH are also endowed with some antiviral activity [38]. Several reports have also stated that ceramide accumulation through a de novo biosynthesis pathway plays an antiviral and a protective role against influenza A/H1N1 virus infection [39]. The previously isolated ceramides were shown to exhibit antiviral activity against the pathogenic H5N1 avian influenza strain [40]. Based on these findings, the previously reported antiviral activity of different Ulva spp. including U. lactuca [19,20,21,22,23,24,25,26,27,28,29] may be attributed to the diverse chemical entities that were detected in this study using the LC-ESI-HRMS technique in addition to the polysaccharides previously extracted from Ulva spp. [11].

2.2. Isolation of Compounds 1–6

Four new ceramides in addition to two known ones (Figure 1) were isolated and purified from the fractions of the crude extract of U. lactuca, and the structures of the isolated compounds were elucidated based on spectroscopic data and by comparison with the data reported in the literature.

2.3. Identification of Isolated Compounds

Compound 1 (Figure 1) was isolated as a white powder. It has a molecular formula of C34H70NO4 derived from its positive HRESIMS pseudo molecular ion at m/z 556.5660 [M + H]+ (Figure S3) (calculated for 556.5305), representing one degree of unsaturation. The 1H spectrum (C5D5N, 400 Hz) of compound 1 is listed in Table 2 using deuterated pyridine as a solvent (Figure S4). The spectrum manifested resonances of an amide proton at δH 8.50 (d, J = 8 Hz) as well as overlapped peaks of protons of a long methylene chain at δH 1.21–1.26, representing a ceramide skeleton. Moreover, resonances of the long-chain base of 2-amino-1,3,4-triol were observed at δH 4.95 (m), 5.07 (m), 4.38 (m), and 4.27 (m) assigned to H-1, H-2, H-3 and H-4, respectively. Resonances of terminal methyl groups at δH 0.84 (t, J = 8 Hz) were assigned to CH3-16 and CH3-18′. On the other hand, the 13C NMR spectrum (C5D5N, 100 Hz) (Table 3) (Figures S5 and S6) showed characteristic resonances of a 2-amino-1,3,4-triol unit of the long-chain base at δC 62.2 (C-1), 53.8 (C-2), 76.7 (C-3) and 73.1 (C-4), while an amide carbonyl group was assigned at δC 173.5 (C-1′). In addition, the terminal methyl groups were detected at δC 14.2 (C16 and C18′) and carbons of long methylene chain were detected at δC 29.6–29.9. GC–MS analysis of the fatty acid methyl esters of compound 1 was performed after its methanolysis showing a peak with a molecular ion of m/z 298 which corresponded to the methyl ester of octadecanoic acid, C (18:0). (Figure S7). The configuration of the ceramide moieties was determined by f 13C NMR comparison with analogs as reported in the literature [49]. Thus, the structure of 1 was determined to be N-[(2S,3R,4R)-1,3,4-trihydroxy-hexadecan-2-yl] octadecanamide. To the best of our knowledge, this compound is considered a new compound. Henceforth, it is denoted as Cer-1.
Compound 2 (Figure 1) was identified as N-[1,3-dihydroxy-octadeca-4,8-diene] hexadecanamide by comparing its spectral data (Table 2 and Table 3) with those reported in the literature [33]. It is worth mentioning that this ceramide was previously isolated from Ulva fasciata and showed antiviral activity against Japanese encephalitis virus [33]. Henceforth, it is denoted as Cer-2.
Compound 3 (Figure 1) was obtained as a white powder, and its molecular formula was determined to be C37H76NO5, as obtained from its HRESIMS pseudo molecular ion at m/z 614.5067 [M + H]+ (Figure S8) (calculated for 614.5723), representing one degree of unsaturation. The 1H NMR (C5D5N, 400 Hz) and 13C NMR (C5D5N, 100 Hz) spectral data of compound 3 are listed in Table 2 and Table 3, respectively, using deuterated pyridine as a solvent (Figures S9 and S10). The spectrum also manifested the sphingolipid skeleton as mentioned above. In addition, the resonance of alpha hydroxy fatty acid was determined at δH 4.60 (t, J = 8 Hz) and δC 72.1 (C-2′). Compound 3 was subjected to hydrolysis then oxidation, using aqueous HCl/MeOH for methanolysis giving an α-hydroxy fatty acid methyl ester and a phytosphingosine base. Then, the α-hydroxy fatty acid methyl ester was converted into a fatty acid methyl ester via oxidative cleavage using KMnO4 and NaIO4 [40]. The resultant fatty acid methyl ester was analyzed by GC–MS which demonstrated a molecular ion peak of m/z 242 corresponding to a C14 fatty acid methyl ester (Figure S11). The assignment of the configuration of the ceramide moiety was accomplished through x 13C NMR data comparison with analogs as reported in the literature [50]. Thus, the structure of 3 was determined to be 2-hydroxyN-[(2S,3R,4R)-1,3,4-trihydroxy-docosan-2-yl] pentadecanamide. To the best of our knowledge, this compound is also considered a new compound. Henceforth, it is denoted as Cer-3.
Compound 4 (Figure 1) was obtained as a white powder, and its molecular formula was determined to be C39H71NNaO5, as established from its HRESIMS pseudo molecular ion at m/z 656.5080 [M + Na]+ (Figure S12) (calculated for 656.5230), representing five degrees of unsaturation. The 1H spectrum (CDCl3, 400 Hz) of compound 4 is listed in Table 2 using deuterated chloroform as a solvent (Figure S13). Additionally, the resonance of α hydroxy fatty acid was determined at δH 4.23 (t, J = 8 Hz). Resonances of the long-chain base of 2-amino-1,3,4-triol were observed as mentioned before, while multiplied olefinic protons were determined at δH 5.32–5.81. On the other hand, the 13C NMR spectrum (CDCl3, 100 Hz) (Table 3) (Figures S14 and S15) showed typical signals of 2-amino-1,3,4-triol in addition to olefinic carbons at δC 126, 129, 132 and 134. Compound 4 was subjected to methanolysis followed by oxidation resulting in a fatty acid methyl ester which was inspected by GC/MS, showing a molecular ion peak of m/z 318 which corresponded to the methyl ester of arachidonic acid, C(20:4) (Figure S16). Thus, the structure of 4 was set to be 2-hydroxy-N-[(2S,3R,4R)-1,3,4-trihydroxy-octadecan-2-yl] henicosa-6,9,12,15-tetraene-amide [51]. To the best of our knowledge, this compound is considered a new compound. Henceforth, it is denoted as Cer-4.
Compound 5 (Figure 1) was obtained as a white powder, and its molecular formula was determined to be C33H65NNaO5, as derived from its HRESIMS pseudo molecular ion at m/z 578.4604 [M + Na]+ (Figure S17) (calculated for 578.4760), representing two degrees of unsaturation. The 1H NMR (C5D5N, 400 Hz) and 13C NMR spectral data (C5D5N, 100 Hz) of compound 3 are listed in Table 2 and Table 3, respectively, showing a ceramide nucleus (Figures S18 and S19). Herein, the olefinic carbons were detected at δC 132.7. It is well established that double bond geometry in a long-chain alkene can be deduced from the 13C-NMR chemical shift of the allylic carbon. In the (Z) isomer, the allylic carbon resonance was observed close to δC 27, while in the (E) isomer, its chemical shift is approximately δC32 [52]. Therefore, the olefinic group is determined to be Z-type. The GC–MS analysis of the fatty acid methyl esters resulted from compound 5 methanolysis and oxidation which displayed a molecular ion peak of m/z 268 corresponding to 9Z-hexadecenoic acid, C (16:1) methyl ester (Figure S20). The configuration of the ceramide part of the compound was determined by 13C NMR comparison with analogues mentioned in the literature [53]. Thus, the structure of 5 was determined to be 2- hydroxy-N-[(2S,3R,4R)-1,3,4-trihydroxy-hexadecan-2-yl]-10-heptadecenamide. To the best of our knowledge, this compound is also considered a new compound. Henceforth, it is denoted by Cer-5.
Compound 6 (Figure 1) was identified as N-[1,3,4,5-tetrahydroxy-octadecan-2-yl] hexadecanamide by comparing its spectral data (Table 2 and Table 3) with those reported in the literature. It is worth noting that this antiviral ceramide was also previously isolated from Ulva fasciata [54]. Henceforth, it is denoted as Cer-6.

2.4. Docking Studies

2.4.1. Molecular Docking Simulation of Isolated Ceramides and Detected Metabolites by LC-ESI-HRMS Technique to Site 4 of hACE2–SARS-CoV-2 Spike Protein Complex

The outbreak of SARS-CoV-2 is currently a global disaster [55], as confirmed cases exceed 250 million in addition to more than 5 million deaths all over the world [56]. Unfortunately, to date, there is no validated treatment for this infection despite several ongoing clinical and preclinical studies [55]. The experimental procedure to obtain a de novo drug is expensive (costing millions of dollars) and long (requiring decades)—and is thus not a solution in the present emergency situation. Thus, in silico studies are playing a significant role in accelerating research to discover potential leads against SARS-CoV-2. Drug repurposing including those of natural origin together with molecular docking and dynamic simulation are the main strategies currently applied for the development of antiviral therapies for the treatment of COVID-19 [57,58,59]. Moreover, molecular dynamic simulation investigations help validate the binding between the protein and the ligand. Such techniques can be employed in drug developmental studies that further help in drug optimization with improved selectivity and specificity [57].
At the present time, numerous natural products are being evaluated for possible antiviral potential against SARS-CoV-2 [55,56,57]. In addition, evidence of the antiviral activities of algae belonging to genus Ulva against both RNA and DNA viruses have been acquired [19,20,21,22,23,24,25,26,27,28,29].
Based on the aforementioned considerations, the phytoconstituents of Ulva lactuca were evaluated by in silico studies as possible leads against SARS-CoV-2
Protein–protein docking demonstrated that SARS-CoV-2 spike proteins possess a strong affinity for hACE2 [6]. Although, many compounds have been shown using virtual screening to inhibit ACE2, these compounds may not be useful for treating SARS-CoV-2 infection because hACE2 is considered a protective factor against lung injury [60]. Only compounds that are able to prevent protein–protein interaction between the spike protein and ACE are considered potential therapeutic agents. One such compound that could target the binding interface between spike protein and ACE2 is hesperidin. It was suggested that the interaction of ACE2 with RBD might be disrupted by hesperidin. Since a clear interlock of the ACE2 interface with hesperidin was noticed by superimposing the ACE2–receptor binding domain (RBD) complex on the hesperidin—RBD complex [61,62]. Hesperidin was predicted to be on the middle shallow pit of the receptor-binding domain (RBD) surface of the spike protein [61]. Thus, this compound in particular was utilized as a reference in the present study.
The crystal structure of the RBD of the spike protein of SARS-CoV-2 in the complex with hACE2 was determined by Shang and collaborators. An hACE2-binding ridge in SARS-CoV-2 RBD possesses a tighter conformation compared to the SARS-CoV-2 RBD. Furthermore, two virus-binding hotspots at the RBD–hACE2 interface were stabilized by numerous residues’ changes in the SARS-CoV-2 RBD. Consequently, the binding affinity of SARS-CoV-2 RBD with hACE2 increased. [63]. We used the crystallographic model for docking studies with the isolated ceramides (Cer-1–6) and the metabolites. Molecular docking simulation results as well as the interaction energies of the ceramides, the metabolites (compounds 1–17) and the reference hesperidin with SARS-CoV-2 spike protein- hACE2 complex are shown in Table 4. All the ceramide compounds and compounds 8 and 16 showed excellent binding energies with hACE2–spike protein compared to hesperidin, while compounds 2–4, 10,11,13,17 showed weaker binding energies than hesperidin. The ceramide compounds Cer-4 and Cer-5 were the most promising compounds and their binding mode with the hACE2–spike protein complex is shown in Figure 2 and Figure 3.

2.4.2. Molecular Docking Simulation of Isolated Ceramides and Detected Metabolites by LC-ESI-HRMS Technique to SARS-CoV-2 Mpro

The proteinase (Mpro)is a key enzyme which plays an essential role in SARS-CoV-2 replication and transcription and its closely related homologues in humans are absent. Therefore, Mpro becomes a druggable e-target for the development of antivirals against SARS-CoV-2 [64]. Drugs that inhibit Mpro are expected to play a crucial role in restricting viral transcription and replication [65,66]. The (Mpro) is specifically involved in proteolytic cleavages of polyproteins to release functional polypeptides. This enzyme digests the polyprotein of at least 11 conserved sites, commencing with the autolytic cleavage from pp1a and pp1ab of the enzyme itself [67]. The Mpro owns a Cys–His catalytic dyad, and the substrate-binding site is present in a cleft between Domains I and II. The crystal structure of Mpro in the complex with a known inhibitor, N3, was determined by Zhenming and coworkers [68], where N3 is inside the substrate-binding pocket. The molecular simulation of the six isolated ceramides, compounds 1–17, and the positive controls N3 and darunavir in the active site of Mpro was performed. All the compounds showed nearly identical bindings such as N3 with interaction energies shown in Table 5. The compounds were stabilized at the N3-binding site of Mpro by many different types of electrostatic interactions. All the ceramide compounds (Cer-1–6) showed excellent binding energies with the best being Cer-4 (94% that of N3) (Figure 4 and Figure 5). Ceramides (Cer-1–6) and compounds 12, 8, 9, 15, 16 also demonstrated higher binding energies compared to darunavir. The other compounds showed only moderate binding energies.

2.4.3. ADME Studies

The evaluation of the in silico drug-likeness and pharmacokinetics of biomolecules is a rapid predictive and cost-effective technique in drug discovery. The studied molecules must demonstrate significant biological activity and low toxicity as well. In addition, the accessibility and concentration of the biologically active molecule at the therapeutic target in the organism is equally essential. It has been demonstrated that the determination of the ADME properties of a potential drug candidate in the discovery phase drastically decreases the chances of drug failure in the clinical phases due to its pharmacokinetic characters [69]. ADME computational models have been recognized as an acceptable alternative to experimental procedures for the prediction of drug pharmacokinetics, particularly at first steps, when studied chemical entities are immense but the availability of such compounds is rare [70]. The topological polar surface area (TPSA), considering sulfur and phosphorus as polar atoms [71], has been a valid descriptor used in the fast estimation of some ADME properties, concerning the crossing of biological barriers such as absorption and brain access [72]. Studying the physicochemical properties and ADME of the six isolated ceramides (Cer-1–6), compounds 1–17, hesperidin, darunavir and N3 (Table 6) revealed that all compounds have a reasonable TPSA, i.e., between 20 and 130 Å2 except for compounds 8, 9 and the references’ compounds. The most promising compounds are predicted to have low absorption from GIT. However, this can be overcome by converting them into prodrugs through the esterification of their hydroxyl groups. An MLOGP of less than 4.15 suggests reasonable lipophilicity suggestive of oral bioavailability. Compounds Cer-5, Cer-6, 1, 2, 7–9, 12, 15–17 and the reference compounds were of reasonable lipophilicity. The predicted BBB permeability is shown in Table 6, indicating the most promising compounds (Cer-1–6) and all compounds except compounds 1–3 will not cause CNS side effects. Noteworthily, all test compounds showed no PAINS (pan assay interference compounds) alert, which reveals that all compounds do not contain pharmacologically unwanted moieties in their chemical structures that could be liberated into the metabolism.

3. Materials and Methods

3.1. Plant Material

The green algae U. lactuca was collected from Safaga on the coast of the Red Sea and was kept in sea water containing plastic bags to prevent evaporation. Then, epiphytes and rock debris were separated. Samples were rinsed with fresh water for the removal of surface salts. Then, samples were air-dried and stored at a low temperature (−24 °C) until further processing. The alga was identified by morphological techniques according to [73,74] by Dr. Tarek Temraz, Marine Science Department, Faculty of Science, Suez Canal University, Ismailia, Egypt. A voucher specimen under registration no. SAA-131 was placed in the Pharmacognosy Department herbarium, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt.

3.2. General Experimental Procedure

A Bruker Avance III HD 400 spectrometer operating at 400 MHz was utilized to obtain 1H and 13C NMR spectra. The chemical shifts of 1H and 13C NMR are expressed in δ (ppm) values regarding the solvent peaks δH 7.26 and δC 77 ppm for CDCl3, and also δH 7.19, 7.55, 8.71 and δC 123.5, 135.5, 149.2 ppm for C5D5N. The coupling constants are obtained in Hertz (Hz). Aluminum-backed plates pre-coated with silica gel F254 (20 × 20 cm; 200 µm; 60 Å (Merck™, Darmstadt, Germany) were used for TLC analysis. For column chromatography, silica gel 60/230–400 µm mesh size (Whatman™, Sanford, ME, USA) was utilized. C18- reversed phase octadecyl silica (ODS) gel (Fluka™, Buchs, Switzerland) and Sephadex® LH-20 (Sigma Aldrich®, Bremen, Germany) were also used for final purification.

3.3. Metabolic Profiling

The metabolic study was carried out using LC-ESI-HRMS for the rapid identification of different primary and secondary metabolites, as previously described in detail [34]. The identification of the phytochemicals was achieved by the comparison of their spectral data, accurate masses in particular, with those from some databases such as METLIN and DNP.

3.4. Extraction and Isolation

The air-dried material of U. lactuca (90 g) was milled and then extracted at room temperature with methanol (MeOH, 2 L × 3). The obtained extracts were combined together and then concentrated in vacuo to yield a dark-green residue (Ulv, 23 g) which was dissolved in a MeOH:H2O (6:4) solvent system and then fractionated by partitioning with different solvents in increasing order of polarity: n-hexane, chloroform, ethyl acetate (EtOAc) and n-butanol. The EtOAc fraction (Ulv-EA, 5.79 g) was chromatographed on a silica gel column using n-hexane: EtOAc: MeOH (80:20:0) up to (0:75:25) and step-by-step gradient elution, giving five subfractions: Ulv-EA-1–Ulv-EA-5. Subfraction Ulv-EA-3 (330 mg) was rechromatographed on silica gel using hexane: EtOAc: methanol (50:50:0) up to (0:90:10) giving five subfractions: Ulv-EA-3-1′–Ulv-EA-3-5′. One of the resulting subfractions (Ulv-EA-3-2′, 43 mg) was purified using octadecyl silica gel column chromatography (ODS column) and methanol: isopropanol (60:40) as an eluent giving compound 1 (13 mg) and compound 2 (11 mg). Another subfraction (Ulv-EA-3-3′, 169 mg) was rechromatographed on silica gel column using EtOAc: methanol (100:0 to 90:10), giving three subfractions: Ulv-EA-3-3′-1–Ulv-EA-3-3′-3. Among them, subfraction Ulv-EA-3-3′-2 (67 mg) was rechromatographed on a sephadex LH-20 column eluted with CHCl3-MeOH (1:1) giving 2 subfractions: Ulv-EA-3-3′-2-1 and Ulv-EA-3-3′-2-2. The first one (EA-3-3′-2-1, 23 mg) was applied to an ODS column using methanol: isopropanol (70:30) to afford 3 (6 mg), 4 (7 mg), while the second one (EA-3-3′-2-2, 27 mg) was also applied to an ODS column using methanol: isopropanol (70:30) to afford 5 (6 mg) and 6 (9 mg).

3.5. Docking Studies

3.5.1. Test Compounds Preparation

After constructing the test compounds as a 3D model and formal charges on atoms were implemented by a 2D model, a conformational search was performed to the test compounds. Energy minimizations were applied to the RMSD gradient of 0.01 Kcal/mole and an RMS distance of 0.1 Å with an MMFF94X force-field with the automatic calculation of the partial charges. The chemical structures with energy minimization were saved as molecular data-based MDB files for docking studies.

3.5.2. Optimization of the Enzymes’ Active Site

From the Protein Data Bank (PDB), the X-ray crystallographic structure of SARS-CoV-2 spike protein–hACE2 complex was downloaded through (http://www.rcsb.org/, PDB code 6VW1) (accessed on 30 August 2020). Additionally, Mpro complexed with N3 was downloaded (http://www.rcsb.org/, PDB code 6LU7) (accessed on 30 August 2020). The optimization of the proteins was achieved by adding hydrogen atoms and the automatic correction of atoms’ connections in the protein. Additionally, the atoms’ potentials were performed. For the identification of the active site of hACE2- SARS-CoV-2–spike protein complex, we utilized site finder. The largest site of the hACE2 complex with the SARS-CoV-2 spike protein was selected from the site finder of the pocket. However, for MPRO, the N3 binding site was selected for docking studies.

3.5.3. Docking of the Test Molecules to the Biggest Site of hACE2 Complex with SARS-CoV-2 Spike Protein and to SARS-CoV-2 Mpro

The conformation of the database of the docking of the target compounds was performed. First, the active site file was loaded and then the docking tool was started. The adjustment of the program specifications to the biggest site of the hACE2 complex with the SARS-CoV-2 spike protein as the docking site (dummy atoms) was performed in addition to applying the alpha triangle as the placement methodology. The scoring methodology London d G was applied for default values. The target compounds’ MDB file was used and fitting calculations were automatically performed. The poses which demonstrated the best reciprocity between the ligand and the contact surface of the hACE2–SARS-CoV-2 spike protein complex were chosen and saved to calculate the binding energy.

3.5.4. ADME Studies

The ADME of all the mentioned compounds of the test compounds isolated from U. lactuca and the reference compounds, hesperidin, darunavir and N3 were calculated by the charge-free website http://www.swissadme.ch (accessed on 5 September 2020).

4. Conclusions

We identified four new ceramides from the methanolic extract of the green algae U. lactuca in addition to two previously reported ceramides. Furthermore, various metabolites such as fatty acids, their glyceride derivatives, terpenoids, sterols and oxysterols were identified using the LC-ESI-HRMS technique. Molecular docking studies with the six isolated ceramides as well as all identified metabolites suggest that these compounds may inhibit viral attachment to host cells or viral replication and transcription. Cer-4, 2- hydroxy-N-[(2S,3R,4R)-1,3,4-trihydroxy-octadecan-2-yl] henicosa-6,9,12,15-tetraene-amide, was the most active compound of the hACE2–SARS-CoV-2 spike protein binding complex inhibition. It also showed the best binding affinity to the MPRO N3 binding site. This study identified potential natural products that could be developed to treat the SARS-CoV-2 virus disease. Future extensive wet-lab in vitro and in vivo studies will be conducted to verify our findings.

Supplementary Materials

The following data are available online at https://www.mdpi.com/article/10.3390/metabo11120816/s1, Figures S1 and S2: LC-ESI-HRMS chromatogram of crude extract of Ulva lactuca (positive and negative modes), Figure S3: ESI–HRMS chromatogram of compound 1, Figures S4–S6: 1H NMR and 13C NMR spectra of compound 1, Figure S7: GC–MS analysis of fatty acid methyl ester of compound 1, Figure S8: ESI–HRMS chromatogram of compound 3, Figures S9 and S10: 1H NMR and 13C NMR spectra of compound 3, Figure S11: GC–MS analysis of fatty acid methyl ester of compound 3, Figure S12: ESI–HRMS chromatogram of compound 4, Figures S13–S15: 1H NMR and 13C NMR spectra of compound 4, Figure S16: GC–MS analysis of fatty acid methyl ester of compound 4, Figure S17: ESI–HRMS chromatogram of compound 5, Figures S18 and S19: 1H NMR and 13C NMR spectra of compound 5, Figure S20: GC–MS analysis of fatty acid methyl ester of compound 5.

Author Contributions

Conceptualization, S.A.A., H.A.H., S.S.E., E.E.E. and A.K.I.; methodology, E.E.E., M.S.G., S.S.E. and E.S.H.; software, S.S.E., E.E.E. and O.M.A.; validation, E.E.E., A.K.I. and M.S.G.; formal analysis, E.E.E., S.S.E., M.S.G. and A.K.I.; investigation, S.S.E., A.K.I., E.E.E., E.S.H., M.S.G. and U.R.A.; resources, S.S.E., M.K.S. and S.A.A.; funding acquisition, M.K.S., S.S.E. and S.A.A.; data curation, A.K.I., E.E.E., H.A.H., M.S.G., S.S.E. and O.M.A.; writing—original draft preparation, E.E.E., E.S.H., S.S.E. and M.S.G.; writing—review and editing, S.A.A., E.E.E., E.S.H., U.R.A. and S.S.E.; supervision, S.S.E., E.E.E., H.A.H., E.S.H. and A.K.I. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Deanship of Scientific Research (DSR) at King Abdulaziz University, Jeddah Saudi Arabia under grant number (RG-20-166-42).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The datasets used in the current study are available from the corresponding author upon reasonable request.

Acknowledgments

The Deanship of Scientific Research (DSR) at King Abdulaziz University, Jeddah Saudi Arabia has funded this project under grant number (RG-20-166-42). The authors, therefore, acknowledge with thanks DSR for technical and financial support. The authors are grateful to Tarek A. Temraz, Marine Science Department, Faculty of Science, Suez Canal University, Egypt, for his taxonomical identification of the Red Sea green algae U. lactuca.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Bosch, B.J.; van der Zee, R.; de Haan, C.A.; Rottier, P.J. The coronavirus spike protein is a class I virus fusion protein: Structural and functional characterization of the fusion core complex. J. Virol. 2003, 77, 8801–88011. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Omrani, A.S.; Saad, M.M.; Baig, K.; Bahloul, A.; Abdul-Matin, M.; Alaidaroos, A.Y.; Almakhlafi, G.A.; Albarrak, M.M.; Memish, Z.A.; Albarrak, A.M. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: A retrospective cohort study. Lancet Infect. Dis. 2014, 14, 1090–1095. [Google Scholar] [CrossRef] [Green Version]
  3. Ge, X.Y.; Li, J.L.; Yang, X.L.; Chmura, A.A.; Zhu, G.; Epstein, J.H.; Mazet, J.K.; Hu, B.; Zhang, W.; Peng, C.; et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 2013, 503, 535–538. [Google Scholar] [CrossRef]
  4. Han, D.P.; Penn-Nicholson, A.; Cho, M.W. Identification of critical determinants on ACE2 for SARS-CoVentry and development of a potent entry inhibitor. Virology 2006, 350, 15–25. [Google Scholar] [CrossRef] [Green Version]
  5. Li, W.; Moore, M.J.; Vasilieva, N.; Sui, J.; Wong, S.K.; Berne, M.A.; Somasundaran, M.; Sullivan, J.L.; Luzuriaga, K.; Greenough, T.C.; et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003, 426, 450–454. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Xu, X.; Chen, P.; Wang, J.; Feng, J.; Zhou, H.; Li, X.; Zhong, W.; Hao, P. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci. China Life Sci. 2020, 63, 457–460. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Oliveira, V.P.; Ignacio, B.L.; Martins, N.T.; Dobler, L.; Enrich-Prast, A. The Ulva spp. Conundrum: What Does the Ecophysiology of Southern Atlantic Specimens Tell Us? J. Mar. Biol. 2019, 2019, 1–6. [Google Scholar] [CrossRef] [Green Version]
  8. Kang, J.H.; Jang, J.E.; Kim, J.H.; Byeon, S.Y.; Kim, S.; Choi, S.K.; Kang, Y.H.; Park, S.R.; Lee, H.J. Species composition, diversity, and distribution of the genus Ulva along the coast of Jeju Island, Korea based on molecular phylogenetic analysis. PLoS ONE 2019, 14, e0219958. [Google Scholar] [CrossRef]
  9. Moustafa, Y.T.; Saeed, S.M. Nutritional evaluation of green macroalgae, Ulva sp. and related water nutrients in the Southern Mediterranean Sea coast, Alexandria shore, Egypt. Egypt. Acad. J. Biol. Sci. 2014, 5, 1–19. [Google Scholar] [CrossRef]
  10. Silva, M.; Vieira, L.; Almeida, A.P.; Kijjoa, A. The marine macroalgae of the genus Ulva: Chemistry, biological activities and potential applications. Oceanography 2013, 1, 1–6. [Google Scholar] [CrossRef]
  11. Kidgell, J.; Magnusson, M.; de Nys, R.; Glasson, C. Ulvan: A systematic review of extraction, composition and function. Algal Res. 2019, 39, 101422. [Google Scholar] [CrossRef]
  12. Abou El Azm, N.; Fleita, D.; Rifaat, D.; Mpingirika, E.Z.; Amleh, A.; El-Sayed, M.M.H. Production of Bioactive Compounds from the Sulfated Polysaccharides Extracts of Ulva lactuca: Post-Extraction Enzymatic Hydrolysis Followed by Ion-Exchange Chromatographic Fractionation. Molecules 2019, 24, 2132. [Google Scholar] [CrossRef] [Green Version]
  13. Chung, Y.; Jeong, S.; Lee, I.-K.; Yun, B.-S.; Lee, J.S.; Ro, S.; Park, J.K. Regulation of p53 Activity by (+)-Epiloliolide Isolated from Ulva lactuca. Mar. Drugs 2021, 19, 450. [Google Scholar] [CrossRef]
  14. Roleda, M.Y.; Lage, S.; Fonn Aluwini, D.; Rebours, C.; Bente Brurberg, M.; Nitschke, U.; Gentili, F.G. Chemical profiling of the Arctic Sea lettuce Ulva lactuca (Chlorophyta) mass-cultivated on land under controlled conditions for food applications. Food Chem. 2021, 341, 127999. [Google Scholar] [CrossRef] [PubMed]
  15. Chakraborty, K.; Dhara, S.; Mani, E.A. Ulvapyrone, a pyrone-linked benzochromene from sea lettuce Ulva lactuca Linnaeus (family Ulvaceae): Newly described anti-inflammatory agent attenuates arachidonate 5-lipoxygenase. Nat. Prod. Res. 2021, 20, 1–11. [Google Scholar] [CrossRef]
  16. Awad, N.E. Biologically active steroid from the green alga Ulva lactuca. Phytother. Res. 2000, 14, 641–643. [Google Scholar] [CrossRef]
  17. El Ashry, E.H.; Atta-ur-Rahman; Choudhary, M.I.; Kandil, S.; El Nemr, A.; Gulzar, T.; Shobier, A. Studies on the constituents of the green alga Ulva lactuca. Chem. Nat. Compd. 2011, 47, 335. [Google Scholar] [CrossRef]
  18. Sun, Y.; Zhan, Y.-C.; Sha, Y.; Pei, Y.-H. Norisoprenoids from Ulva lactuca. J. Asian Nat. Prod. Res. 2007, 9, 321–325. [Google Scholar] [CrossRef]
  19. Zaid, S.A.A.L.; Hamed, N.N.E.D.; Abdel-Wahab, K.S.E.D.; Abo El-Magd, E.K.; Salah El-Din, R.A.L. Antiviral activities and phytochemical constituents of Egyptian marine seaweeds (Cystoseiramyrica (SG Gmelin) C. Agardh and Ulva lactuca Linnaeus) aqueous extract. Egypt. J. Hosp. Med. 2016, 64, 422–429. [Google Scholar] [CrossRef]
  20. Mendes Gda, S.; Soares, A.R.; Martins, F.O.; Albuquerque, M.C.; Costa, S.S.; Yoneshigue-Valentin, Y.; Gestinari, L.M.; Santos, N.; Romanos, M.T. Antiviral activity of the green marine alga Ulva fasciata on the replication of human metapneumovirus. Rev. Inst. Med. Trop. Sao Paulo 2010, 52, 3–10. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  21. Soares, A.R.; Robaina, M.; Mendes, G.S.; Silva, T.S.; Gestinari, L.; Pamplona, O.S.; Gestinari, L.M.; Yoneshigue-Valentin, Y.; Kaiser, C.; Romanos, M.; et al. Antiviral activity of extracts from Brazilian seaweeds against herpes simplex virus. Rev. Bras. Farmacogn. 2012, 22, 714–723. [Google Scholar] [CrossRef] [Green Version]
  22. Hudson, J.B.; Kim, J.H.; Lee, M.K.; Hong, Y.L. Antiviral compounds in extracts of Korean seaweeds: Evidence for multiple activities. J. Appl. Phycol. 1998, 10, 427. [Google Scholar] [CrossRef]
  23. Hudson, J.B.; Kim, J.H.; Lee, M.K.; Hong, Y.K.; DeWreede, R.E. Multiple antiviral activities in extracts of seaweeds from British Columbia. Pharm. Biol. 1999, 37, 300–306. [Google Scholar] [CrossRef]
  24. Ktari, L. Pharmacological Potential of Ulva Species: A Valuable Resource. J. Anal. Pharm. Res. 2017, 6, 00165. [Google Scholar]
  25. Deyab, M.; Mofeed, J. Evaluation of Biochemical composition and bioactivities of two Ulva species (Ulva lactuca and Ulva fasciata); a comparative study. Biosci. Res. 2019, 16, 3801–3811. [Google Scholar]
  26. Elyamany, K.; Ibraheem, I.; Abdel-Raouf, N.; Abdel-Hameed, M. Antimicrobial and antiviral activities against Newcastle disease virus (NDV) from marine algae isolated from Qusier and Marsa-Alam Seashore (Red Sea), Egypt. Afr. J. Biotechnol. 2012, 11, 8332–8340. [Google Scholar]
  27. Ivanova, V.; Rouseva, R.; Kolarova, M.; Serkedjieva, J.; Rachev, R.; Manolova, N. Isolation of a polysaccharide with antiviral effect from Ulva lactuca. Prep. Biochem. 1994, 24, 83–97. [Google Scholar] [CrossRef]
  28. Aguilar-Briseño, J.A.; Cruz-Suarez, L.E.; Sassi, J.-F.; Ricque-Marie, D.; Zapata-Benavides, P.; Mendoza-Gamboa, E.; Rodríguez-Padilla, C.; Trejo-Avila, L.M. Sulphated Polysaccharides from Ulva clathrate and Cladosiphon okamuranus Seaweeds both Inhibit Viral Attachment/Entry and Cell-Cell Fusion, in NDV Infection. Mar. Drugs 2015, 13, 697–712. [Google Scholar] [CrossRef]
  29. Sun, Y.; Chen, X.; Song, L.; Liu, S.; Yu, H.; Wang, X.; Qin, Y.; Li, P. Antiviral activity against avian leucosis virus subgroup J of degraded polysaccharides from Ulva pertusa. BioMed. Res. Int. 2018, 5, 9415965. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  30. Lin, K.H.; Liang, J.J.; Huang, W.I.; Lin-Chu, S.Y.; Su, C.Y.; Lee, Y.L.; Jan, J.T.; Lin, Y.L.; Cheng, Y.S.; Wong, C.H. In vivo protection provided by a synthetic new alpha-galactosyl ceramide analog against bacterial and viral infections in murine models. Antimicrob. Agents Chemother. 2010, 54, 4129. [Google Scholar] [CrossRef] [Green Version]
  31. Soudani, N.; Hage-Sleiman, R.; Karam, W.; Dbaibo, G.; Zaraket, H. Ceramide Suppresses Influenza A Virus Replication In Vitro. J. Virol. 2019, 93, e00053-19. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Yoshida, H.; Ikeda, K.; Achiwa, K.; Hoshino, H. Synthesis of sulfated cerebroside analogs having mimicks of ceramide and their anti-human immunodeficiency virus type 1 activities. Chem. Pharm. Bull. 1995, 43, 594–602. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Sharma, M.; Garg, H.S.; Chandra, K. Erythro-sphinga-4,8-dienine-N-palmitate: An Antiviral Agent from the Green Alga Ulva fasciata. Bot. Mar. 1996, 39, 1–6. [Google Scholar] [CrossRef]
  34. Abdelhameed, R.F.A.; Habib, E.S.; Goda, M.S.; Fahim, J.R.; Hassanean, H.A.; Eltamany, E.E.; Ibrahim, A.K.; AboulMagd, A.M.; Fayez, S.; El-kader, A.M.A.; et al. Thalassosterol, a New Cytotoxic Aromatase Inhibitor Ergosterol Derivative from the Red Sea Seagrass Thalassodendron ciliatum. Mar. Drugs 2020, 18, 354. [Google Scholar] [CrossRef]
  35. Thormar, H.; Isaacs, C.E.; Kim, K.S.; Brown, H.R. Inactivation of visna virus and other enveloped viruses by free fatty acids and monoglycerides. Ann. N. Y. Acad. Sci. 1994, 724, 465–471. [Google Scholar] [CrossRef]
  36. Abid Ali Khan, M.M.; Jain, D.C.; Bhakuni, R.S.; Zaim, M.; Thakur, R.S. Occurrence of some antiviral sterols in Artemisia annua. Plant Sci. 1991, 75, 161–165. [Google Scholar] [CrossRef]
  37. Ingallinella, P.; Bianchi, E.; Ladwa, N.A.; Wang, Y.J.; Hrin, R.; Veneziano, M.; Bonelli, F.; Ketas, T.J.; Moore, J.P.; Miller, M.D.; et al. Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc. Natl. Acad. Sci. USA 2009, 106, 5801–5806. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  38. Lembo, D.; Cagno, V.; Civra, A.; Poli, G. Oxysterols: An emerging class of broad-spectrum antiviral effectors. Mol. Aspects Med. 2016, 49, 23–30. [Google Scholar] [CrossRef]
  39. Zhou, Y.; Pu, J.; Wu, Y. The Role of Lipid Metabolism in Influenza A Virus Infection. Pathogens 2021, 10, 303. [Google Scholar] [CrossRef]
  40. Ahmed, S.; Ibrahim, A.; Arafa, A.S. Anti-H5N1 virus metabolites from the Red Sea soft coral, Sinularia candidula. Tetrahedron Lett. 2013, 54, 2377–2381. [Google Scholar] [CrossRef]
  41. Alamsjah, M.A.; Hirao, S.; Ishibashi, F.; Fujita, Y. Isolation and structure determination of algicidal compounds from Ulva fasciata. Biosci. Biotechnol. Biochem. 2005, 69, 2186–2192. [Google Scholar] [CrossRef] [Green Version]
  42. van Ginneken, V.J.; Helsper, J.P.; de Visser, W.; van Keulen, H.; Brandenburg, W.A. Polyunsaturated fatty acids in various macroalgal species from north Atlantic and tropical seas. Lipids Health Dis. 2011, 10, 104. [Google Scholar] [CrossRef] [Green Version]
  43. Venkatesalu, V.; Sundaramoorthy, M.; Chandrasekaran, M.; Senthilkumar, A. Seasonal variation on fatty acid composition of some marine macro algae from Gulf of Mannar Marine Biosphere Reserve, Southeast coast of India. Indian J. Mar. Sci. 2012, 41, 442–450. [Google Scholar]
  44. Sun, Y.; Wang, H.; Guo, G.L.; Pu, Y.F.; Yan, B.L.; Wang, C.H. Isolation, purification, and identification of antialgal substances in green alga Ulva prolifera for antialgal activity against the common harmful red tide microalgae. Environ. Sci. Pollut. Res. Int. 2016, 23, 1449–1459. [Google Scholar] [CrossRef] [PubMed]
  45. Li, G.; Guo, W.; Wang, G.; Wang, R.; Hou, Y.; Liu, K.; Liu, Y.; Wang, W. Sterols from the green alga Ulva australis. Mar. Drugs 2017, 15, 299. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Wang, J.; Li, N.; Jiang, P.; Boo, S.M.; Lee, W.J.; Cui, Y.; Hanzhi, L.; Jin, Z.; Zhengyi, L.; Qin, S. Ulva and Enteromorpha (Ulvaceae, Chlorophyta) from two sides of the Yellow Sea: Analysis of nuclear rDNA ITS and plastid rbcL sequence data. Chin. J. Oceanol. Limnol. 2010, 28, 762–768. [Google Scholar] [CrossRef] [Green Version]
  47. Muralidhar, P.; Radhika, P.; Krishna, N.; Venkata-Rao, D.; Bheemasankara-Rao, C. Sphingolipids from Marine Organisms: A Review. Nat. Prod. Sci. 2003, 9, 117–142. [Google Scholar]
  48. Chakraborty, K.; Paulraj, R. Sesquiterpenoids with free-radical-scavenging properties from marine macroalga Ulva fasciata Delile. Food Chem. 2010, 122, 31–41. [Google Scholar] [CrossRef]
  49. Meyer, M.; Guyot, M. New Sphingosines from the Marine Sponge Grayella cyatophora. J. Nat. Prod. 2002, 65, 1722–1723. [Google Scholar] [CrossRef]
  50. Inagaki, M.; Ikeda, Y.; Kawatake, S.; Nakamura, K.; Tanaka, M.; Misawa, E.; Yamada, M.; Higuchi, R. Isolation and structure of four new ceramides from the Starfish Luidia maculate. Chem. Pharm. Bull. 2006, 54, 1647–1649. [Google Scholar] [CrossRef] [Green Version]
  51. Johnson, D.E.; Heald, S.L.; Dally, R.D.; Janis, R.A. Isolation, identification and synthesis of an endogenous arachidonic amide that inhibits calcium channel antagonist 1,4-dihydropyridine binding. Prostaglandins, Leukot. Essent. Fatty Acids 1993, 48, 429–437. [Google Scholar] [CrossRef]
  52. Inagaki, M.; Isobe, R.; Kawano, Y.; Miyamoto, T.; Komori, T.; Higuchi, R. Isolation and structure of three new ceramides from the Starfish Acanthaster planci. Eur. J. Org. Chem. 1998, 1998, 129–131. [Google Scholar] [CrossRef]
  53. Qu, Y.; Zhangb, H.; Liua, J. Isolation and Structure of a New Ceramide from the Basidiomycete Hygrophorus eburnesus. Z. Nat. 2004, 59, 241–244. [Google Scholar]
  54. Garg, H.S.; Sharma, M.; Bhakuni, D.S.; Pramanik, B.N.; Bose, A.K. An antiviral sphingosine derivative from the green alga Ulva fasciata. Tetrahedron Lett. 1992, 33, 1641–1644. [Google Scholar] [CrossRef]
  55. Cavasotto, C.N.; Di Filippo, J.I. In silico Drug Repurposing for COVID-19: Targeting SARS-CoV-2 Proteins through Docking and Consensus Ranking. Mol. Inform. 2021, 40, e2000115. [Google Scholar] [CrossRef] [PubMed]
  56. WHO Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int/ (accessed on 11 November 2021).
  57. Kulkarni, S.A.; Krishnan, S.B.B.; Chandrasekhar, B.; Banerjee, K.; Sohn, H.; Madhavan, T. Characterization of Phytochemicals in Ulva intestinalis L. and Their Action against SARS-CoV-2 Spike Glycoprotein Receptor-Binding Domain. Front. Chem. 2021, 9, 735768. [Google Scholar] [CrossRef]
  58. Romeo, I.; Mesiti, F.; Lupia, A.; Alcaro, S. Current Updates on Naturally Occurring Compounds Recognizing SARS-CoV-2 Druggable Targets. Molecules 2021, 26, 632. [Google Scholar] [CrossRef]
  59. Anand, A.V.; Balamuralikrishnan, B.; Kaviya, M.; Bharathi, K.; Parithathvi, A.; Arun, M.; Senthilkumar, N.; Velayuthaprabhu, S.; Saradhadevi, M.; Al-Dhabi, N.A.; et al. Medicinal Plants, Phytochemicals, and Herbs to Combat Viral Pathogens Including SARS-CoV-2. Molecules 2021, 26, 1775. [Google Scholar] [CrossRef]
  60. Ye, R.; Liu, Z. ACE2 exhibits protective effects against LPS-induced acute lung injury in mice by inhibiting the LPS-TLR4 pathway. Exp. Mol. Pathol. 2019, 113, 104350. [Google Scholar] [CrossRef]
  61. Wu, C.; Liu, Y.; Yang, Y.; Zhang, P.; Zhong, W.; Wang, Y.; Wang, Q.; Xu, Y.; Li, M.; Li, X.; et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm. Sin. B 2020, 10, 766–788. [Google Scholar] [CrossRef] [PubMed]
  62. Bellavite, P.; Donzelli, A. Hesperidin and SARS-CoV-2: New Light on the Healthy Function of Citrus Fruits. Antioxidants 2020, 9, 742. [Google Scholar] [CrossRef]
  63. Shang, J.; Ye, G.; Shi, K.; Wan, Y.; Luo, C.; Aihara, H.; Geng, Q.; Auerbach, A.; Li, F. Structural basis of receptor recognition by SARS-CoV-2. Nature 2020, 581, 221–224. [Google Scholar] [CrossRef] [Green Version]
  64. Pillaiyar, T.; Manickam, M.; Namasivayam, V.; Hayashi, Y.; Jung, S.H. An Overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy. J. Med. Chem. 2016, 59, 6595–6628. [Google Scholar] [CrossRef] [PubMed]
  65. Yang, H.; Yang, M.; Ding, Y.; Liu, Y.; Lou, Z.; Zhou, Z.; Sun, L.; Mo, L.; Ye, S.; Pang, H.; et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc. Natl. Acad. Sci. USA 2003, 100, 13190–13195. [Google Scholar] [CrossRef] [Green Version]
  66. Anand, K.; Palm, G.J.; Mesters, J.R.; Siddell, S.G.; Ziebuhr, J.; Hilgenfeld, R. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain. EMBO J. 2002, 21, 3213–3224. [Google Scholar] [CrossRef]
  67. Hegyi, A.; Ziebuhr, J. Conservation of substrate specificities among coronavirus main proteases. J. Gen. Virol. 2002, 83, 595–599. [Google Scholar] [CrossRef] [PubMed]
  68. Jin, Z.; Du, X.; Xu, Y.; Deng, Y.; Liu, M.; Zhao, Y.; Zhang, B.; Li, X.; Zhang, L.; Peng, C.; et al. Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature 2020, 582, 289–293. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  69. Hay, M.; Thomas, D.W.; Craighead, J.L.; Economides, C.; Rosenthal, J. Clinical development success rates for investigational drugs. Nat. Biotechnol. 2014, 32, 40–51. [Google Scholar] [CrossRef] [PubMed]
  70. Dahlin, J.L.; Inglese, J.; Walters, M.A. Mitigating risk in academic preclinical drug discovery. Nat. Rev. Drug Discov. 2015, 14, 279–294. [Google Scholar] [CrossRef]
  71. Ertl, P.; Rohde, B.; Selzer, P. Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties. J. Med. Chem. 2000, 43, 3714. [Google Scholar] [CrossRef]
  72. Daina, A.; Zoete, V. A boiled-egg to predict gastrointestinal absorption and brain penetration of small molecules. Chem. Med. Chem. 2016, 11, 1117–1121. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  73. Abbott, I.A.; Hollenberg, J. Marine Algae of California; Stanford University Press: Stanford, CA, USA, 1976; p. 827. [Google Scholar]
  74. Taylor, F.J.R. The Taxonomy and Relationships of Red Tide Flagellates. In Toxic Dinoflagellates; Anderson, D.M., White, A.W., Baden, D.G., Eds.; Elsevier: Amsterdam, The Netherlands, 1985; pp. 11–26. [Google Scholar]
Metabolites 11 00816 g001 550
Figure 1. Chemical structures of isolated compounds 1–6.
Figure 1. Chemical structures of isolated compounds 1–6.
Metabolites 11 00816 g001
Metabolites 11 00816 g002 550
Figure 2. 2D representation of the docking of compounds Cer-5 (a); Cer-4 (b); and hesperidin (c) into the SARS-CoV-2 spike binding site with hACE2.
Figure 2. 2D representation of the docking of compounds Cer-5 (a); Cer-4 (b); and hesperidin (c) into the SARS-CoV-2 spike binding site with hACE2.
Metabolites 11 00816 g002
Metabolites 11 00816 g003 550
Figure 3. 3D representation of the docking of compounds Cer-5 (a); Cer-4 (b); and hesperidin (c) into the SARS-CoV-2 spike binding site with hACE2.
Figure 3. 3D representation of the docking of compounds Cer-5 (a); Cer-4 (b); and hesperidin (c) into the SARS-CoV-2 spike binding site with hACE2.
Metabolites 11 00816 g003
Metabolites 11 00816 g004 550
Figure 4. 2D representation of the docking of compounds Cer-4 (a); darunavir (b); and N3 (c) into the SARS-CoV-2 Mpro.
Figure 4. 2D representation of the docking of compounds Cer-4 (a); darunavir (b); and N3 (c) into the SARS-CoV-2 Mpro.
Metabolites 11 00816 g004
Metabolites 11 00816 g005 550
Figure 5. 3D representation of the docking of compounds Cer-4 (a); darunavir (b); and N3 (c) into the SARS-CoV-2 Mpro.
Figure 5. 3D representation of the docking of compounds Cer-4 (a); darunavir (b); and N3 (c) into the SARS-CoV-2 Mpro.
Metabolites 11 00816 g005
Table
Table 1. Metabolic profiling (LC-ESI-HRMS) of methanolic crude extract of U. lactuca.
Table 1. Metabolic profiling (LC-ESI-HRMS) of methanolic crude extract of U. lactuca.
Polarity ModeRet. Time (min)Precursor m/zMZmine IDDetected MassExpected
Mass		Mass Error (ppm)NameStructureReported Previously inRef.
1. Fatty acids
1Positive7.14249.18545976248.1781248.17762.01Hexadeca-4,7,10,13-tetraenoic acid Metabolites 11 00816 i001Ulva fasciata[41]
2Negative10.13295.2267667296.2340296.2351−3.7111E-Oxo-octadec-12-enoic acid Metabolites 11 00816 i002Ulva fasciata[41]
3Negative10.52275.20053655276.2078276.2089−3.986Z,9Z,12Z,15Z-Octadecatetraenoic acid Metabolites 11 00816 i003Ulva fasciata[41]
4Positive11.04305.2479565304.2406304.24021.31Arachidonic acid Metabolites 11 00816 i004Ulva lactuca[42]
5Negative11.15277.21612459278.2234278.2246−4.31Linolenic acid Metabolites 11 00816 i005Ulva fasciata[41]
6Negative11.84283.26272827284.2700284.2715−5.28Stearic acid Metabolites 11 00816 i006Ulva fasciata[43]
2. Glycerol derivatives/glycerides
7Positive8.97331.2874145330.2774330.27701.21Glycerol monopalmitate Metabolites 11 00816 i007Ulva prolifera[44]
8Positive9.40521.37238312520.3650520.36117.491-O-Octadecanoic acid-3-O-β-D-galactopyranosyl glycerol Metabolites 11 00816 i008Ulva prolifera[44]
9Negative10.02491.32222431492.3295492.3298−0.611-O-Palmitoyl-3-O-β-D-galactopyranosyl glycerol Metabolites 11 00816 i009Ulva prolifera[44]
3. Sterols and oxysterols
10Positive10.41443.35245136442.3452442.34471.135,28-Stigmastadiene-3β,24-diol-7-one Metabolites 11 00816 i010Ulva australis[45]
11Negative13.85395.31602931396.3353396.3392−9.84Ergosterol Metabolites 11 00816 i011Ulva pertusa[46]
12Positive15.25575.43626572574.4239574.42331.043-O-β-D Glucopyranosyl-clerosterol Metabolites 11 00816 i012Ulva lactuca[16]
13Positive16.52429.37155560428.3643428.3654−2.5724,28-Epoxy-24-ethylcholesterol Metabolites 11 00816 i013Ulva australis[45]
14Positive16.52429.37155560428.3643428.3654−2.575,28-Stigmastadiene-3β,24-diol Metabolites 11 00816 i014Ulva australis[45]
4. Ceramide and sphingoid base
15Positive12.34328.31986410327.3125327.3137−3.67N,N-Dimethyl
sphingosine		 Metabolites 11 00816 i015fungi[42]
16Positive14.35558.51287471557.5055557.50196.46N-[pentadecanoate ]-1,3,4,5-tetrahydroxy-2-amino-octadecane Metabolites 11 00816 i016Ulva fasciata[47]
5. Terpenoid
17Positive9.06223.20615846222.1988222.19841.802,5,5-Trimethyl-4-(4′-methyl-3′-pentenyl)-2-cyclohexen-1-ol Metabolites 11 00816 i017Ulva fasciata[48]
Table
Table 2. 1H NMR spectra of isolated compounds 1–6.
Table 2. 1H NMR spectra of isolated compounds 1–6.
Cer-1 *Cer-2 *Cer-3 *Cer-4 #Cer-5 *Cer-6 *
14.95 (m)4.53 (m)4.42 (m)4.06 (m)4.60 (m)4.54 (m)
25.07 (m)5.04 (m)5.06 (m)5.08 (m)5.12 (m)5.11 (m)
34.38 (m)4.94 (m)4.39 (m)3.87 (m)4.27 (m)4.44 (m)
44.27 (m)5.46 (m)4.31 (m)3.75 (m)4.44 (m)4.41 (m)
52.22 (m)5.46 (m)2.18 (m)1.99 (m)2.10 (m)4.43 (m)
61.97 (m)2.19 (m)1.10–1.26 (m)1.28–1.36 (m)1.22–1.28 (m)2.02 (m)
71.21–1.26 (m)1.94 (m)1.10–1.26 (m)1.28–1.36 (m)1.22–1.28 (m)1.25–1.30 (m)
81.21–1.26 (m)5.46 (m)1.10–1.26 (m)1.28–1.36 (m)1.22–1.28 (m)1.25–1.30 (m)
91.21–1.26 (m)5.46 (m)1.10–1.26 (m)1.28–1.36 (m)1.22–1.28 (m)1.25–1.30 (m)
101.21–1.26 (m)1.90 (m)1.10–1.26 (m)1.28–1.36 (m)1.22–1.28 (m)1.25–1.30 (m)
111.21–1.26 (m)1.23–1.29 (m)1.10–1.26 (m)1.28–1.36 (m)1.22–1.28 (m)1.25–1.30 (m)
121.21–1.26 (m)1.23–1.29 (m)1.10–1.26 (m)1.28–1.36 (m)1.22–1.28 (m)1.25–1.30 (m)
131.21–1.26 (m)1.23–1.29 (m)1.10–1.26 (m)1.28–1.36 (m)1.22–1.28 (m)1.25–1.30 (m)
141.67 (m)1.23–1.29 (m)1.10–1.26 (m)1.28–1.36 (m)1.22–1.28 (m)1.25–1.30 (m)
151.35 (m)1.23–1.29 (m)1.10–1.26 (m)1.28–1.36 (m)1.36 (m)1.25–1.30 (m)
160.84 (t, J = 8)1.23–1.29 (m)1.10–1.26 (m)1.28–1.36 (m)0.85 (t, J = 8)1.25–1.30 (m)
17-1.68 (m)1.10–1.26 (m)1.28–1.36 (m)-1.71 (m)
18-0.84 (t, J = 8)1.10–1.26 (m)0.84 (t, J = 8)-0.85 (t, J = 8)
19--1.10–1.26 (m)---
20--1.10–1.26 (m)---
21--1.70 (m)---
22--0.81 (t, J = 4)---
1′-------
2′2.45 (t, J = 8)4.19 (brt, J = 4)4.60 (t, J = 8)4.23 (t, J = 8)4.97 (t, J = 8)2.23 (brt, J = 4)
3′1.84 (m)1.98 (m)1.95 (m)1.95 (m)2.10 (m)1.71 (m)
4′1.21–1.26 (m)1.23–1.29 (m)1.10–1.26 (m)1.28–1.36 (m)1.22–1.28 (m)1.25–1.30 (m)
5′1.21–1.26 (m)1.23–1.29 (m)1.10–1.26 (m)1.28–1.36 (m)1.22–1.28 (m)1.25–1.30 (m)
6′1.21–1.26 (m)1.23–1.29 (m)1.10–1.26 (m)5.77 (m)1.22–1.28 (m)1.25–1.30 (m)
7′1.21–1.26 (m)1.23–1.29 (m)1.10–1.26 (m)5.77 (m)1.22–1.28 (m)1.25–1.30 (m)
8′1.21–1.26 (m)1.23–1.29 (m)1.10–1.26 (m)1.28–1.36 (m)1.22–1.28 (m)1.25–1.30 (m)
9′1.21–1.26 (m)1.23–1.29 (m)1.10–1.26 (m)5.53 (m)2.26 (m)1.25–1.30 (m)
10′1.21–1.26 (m)1.23–1.29 (m)1.10–1.26 (m)5.53 (m)5.5 (m)1.25–1.30 (m)
11′1.21–1.26 (m)1.23–1.29 (m)1.10–1.26 (m)1.28–1.36 (m)5.5 (m)1.25–1.30 (m)
12′1.21–1.26 (m)1.23–1.29 (m)1.10–1.26 (m)5.45 (m)2.26 (m)1.25–1.30 (m)
13′1.21–1.26 (m)1.23–1.29 (m)1.10–1.26 (m)5.45 (m)1.22–1.28 (m)1.25–1.30 (m)
14′1.21–1.26 (m)1.23–1.29 (m)1.70 (m)1.28–1.36 (m)1.22–1.28 (m)1.25–1.30 (m)
15′1.21–1.26 (m)1.68 (m)0.81 (t, J = 4)5.34 (m)1.22–1.28 (m)1.71 (m)
16′1.67 (m)0.84 (t, J = 8)-5.34 (m)1.36 (m)0.85 (t, J = 8)
17′1.35 (m)--1.28–1.36 (m)0.85 (t, J = 8)-
18′0.84 (t, J = 8)---1.28–1.36 (m)--
19′---1.28–1.36 (m)--
20′---1.74 (m)--
21′---0.84 (t, J = 8)--
NH8.50 (d, J = 8)8.57 (d, J = 12)8.52 (d, J = 12)7.25 (d, J = 12)8.58 (d, J = 8)8.55 (d, J = 12)
*: 1H NMR spectra using deuterated pyridine (C5D5N) as a solvent; #: 1H NMR spectra using deuterated chloroform (CDCl3) as a solvent.
Table
Table 3. 13C NMR spectra of isolated compounds 1–6.
Table 3. 13C NMR spectra of isolated compounds 1–6.
Cer-1 *Cer-2 * Cer-3 *Cer-4 #Cer-5 *Cer-6 *
162.262.661.761.961.761.9
253.854.552.654.452.652.9
376.775.1 (72)76.577.276.472.4
473.1131.172.774.072.773.0
533.9132.033.832.533.876.6
629.6–29.932.929.2–30.027.329.3–29.634.0
729.6–29.928.029.2–30.029.3–29.729.3–29.629.5–30.2
829.6–29.9131.929.2–30.029.3–29.729.3–29.629.5–30.2
929.6–29.9129.929.2–30.029.3–29.729.3–29.629.5–30.2
1029.6–29.939.929.2–30.029.3–29.729.3–29.629.5–30.2
1129.6–29.929.5–29.929.2–30.029.3–29.729.3–29.629.5–30.2
1229.6–29.929.5–29.929.2–30.029.3–29.729.3–29.629.5–30.2
1329.6–29.929.5–29.929.2–30.029.3–29.729.3–29.629.5–30.2
1429.6–29.929.5–29.929.2–30.029.3–29.729.3–29.629.5–30.2
1522.929.5–29.929.2–30.029.3–29.731.829.5–30.2
1614.231.929.2–30.031.613.932.0
17-22.829.2–30.022.6-22.6
18-14.129.2–30.014.0-14.1
19--29.2–30.0---
20--29.2–30.0---
21--31.8---
22--13.9---
1′173.5175.7175.1175.7175.1175.3
2′36.935.672.172.572.135.6
3′29.6–29.925.735.334.535.326.5
4′29.6–29.929.4–29.929.2–30.029.3–29.727.029.5–30.2
5′29.6–29.929.4–29.929.2–30.029.3–29.729.3–29.629.5–30.2
6′29.6–29.929.4–29.929.2–30.0134.129.3–29.629.5–30.2
7′29.6–29.929.4–29.929.2–30.0134.129.3–29.629.5–30.2
8′29.6–29.929.4–29.929.2–30.029.3–29.722.529.5–30.2
9′29.6–29.929.4–29.929.2–30.0132.526.029.5–30.2
10′29.6–29.929.4–29.929.2–30.0132.5132.729.5–30.2
11′29.6–29.929.4–29.929.2–30.029.3–29.7132.729.5–30.2
12′29.6–29.929.4–29.929.2–30.0131.326.029.5–30.2
13′29.6–29.929.4–29.929.2–30.0131.329.3–29.629.5–30.2
14′29.6–29.931.931.829.3–29.729.3–29.632.0
15′29.6–29.922.813.9129.029.3–29.622.6
16′29.6–29.914.1-126.731.814.1
17′22.9--29.3–29.713.9-
18′14.2---29.3–29.7--
19′---31.6--
20′---22.6--
21′---14.0--
*: 13C NMR spectra using deuterated pyridine (C5D5N) as a solvent; #: 13C NMR spectra using deuterated chloroform (CDCl3) as a solvent.
Table
Table 4. Receptor interaction of isolated ceramides, compounds 1–17 and hesperidin into the SARS-CoV-2 Spike binding site with hACE2.
Table 4. Receptor interaction of isolated ceramides, compounds 1–17 and hesperidin into the SARS-CoV-2 Spike binding site with hACE2.
CompounddG Kcal/moleReceptor
Amino Acid/Type of Bonding/Distance (Å)/Binding Energy (Kcal/mole)
hACE2Spike Protein
Cer-1−8.2488GLU 37/H-donor/3.03/−3.2
ARG 393/H-acceptor/3.37/−0.6		-
Cer-2−8.0390GLU 37/H-donor/2.85/−7.0-
Cer-3−8.3111GLU 37/H-donor/2.88/−2.4-
Cer-4−9.6464HIS 34/H-donor/3.45/−1.0
HIS 34/H-acceptor/3.38/−0.7		LYS 403/H-acceptor/2.06/−0.5
Cer-5−8.7077GLU 37/H-donor/2.71/−3.1
HIS 34/H-pi/3.64/−1.4		GLY 496/H-acceptor/3.04/−1.7
LYS 403/H-acceptor/2.98/−4.9
Cer-6−8.6033GLU 37/H-donor/2.85/−2.8
GLU 37/H-donor/2.74/−2.8
ARG 393/H-acceptor/2.88/−4.1
HIS 34/H-pi/3.76/−1.4		-
1−6.0580--
2−5.9953LYS 353/H-acceptor/3.23/−1.8-
3−5.9901GLU 37/H-donor/2.94/−6.4-
4−5.5072--
5−6.0686HIS 34/H-donor/3.50/−0.6-
6−6.2414--
7−6.5090-ASP 406/H-donor/2.90/−3.7
LYS 403/H-acceptor/3.05/−2.3
8−8.4482GLU 37/H-donor/2.80/−3.6
HIS 34/H-pi/3.91/−1.3		LYS 403/H-acceptor/3.05/−7.5
ARG 408/H-acceptor/2.99/−2.8
LYS 403/H-acceptor/3.10/−4.7
9−7.7408GLU 37/H-donor/2.90/−2.2-
10−5.8042HIS 34/H-pi/3.72/−1.2-
11−4.9095--
12−6.5362-SER 494/H-donor/2.89/−2.5
LYS 403/H-acceptor/2.93/−3.7
GLY 496/H-acceptor/3.38/−0.9
13−5.8862HIS 34/H-pi/3.7
3/−1.2		LYS 403/H-acceptor/2.92/−7.0
14−5.4205HIS 34/H-pi/3.76/−0.7-
15−6.1762--
16−8.6033GLU 37/H-donor/2.85/−2.8
GLU 37/H-donor/2.74/−2.8
ARG 393/H-acceptor/2.88/−4.1
HIS 34/H-pi/3.76/−1.4		-
17−4.1495-LYS 403/H-acceptor/2.80/−4.2
Hesperidin−6.0117-ASP 405/H-donor/2.91/−1.8
Table
Table 5. Receptor interaction of isolated ceramides, compounds 1–17, darunavir and N3 into the SARS-CoV-2 Mpro.
Table 5. Receptor interaction of isolated ceramides, compounds 1–17, darunavir and N3 into the SARS-CoV-2 Mpro.
CompounddG Kcal/moleReceptor
Amino Acid/Type of Bonding/Distance (Å)/Binding Energy (Kcal/mole)
Cer-1−7.4765HIS 41/H-pi/4.08/−0.7
Cer-2−7.1107-
Cer-3−7.5529THR 190/H-donor/2.77/−1.7
GLU 166/H-donor/2.85/−2.4
MET 165/H-donor/3.57/−1.6
Cer-4−7.9390HIS 41/H-pi/4.38/−0.6
Cer-5−7.4910-
Cer-6−6.7077GLY 143/H-acceptor/3.09/−0.7
HIS 41/H-pi/4.74/−0.6
1−5.9111HIS 163/H-acceptor/2.96/−7.3
2−6.2654HIS 41/H-pi/4.07/−1.1
3−6.0563GLU 166/H-donor/3.05/−2.9
HIS 163/H-acceptor/3.06/−5.1
4−6.3289-
5−6.3581-
6−5.8555-
7−6.0696THR 190/H-donor/2.96/−1.2
GLU 166/H-acceptor/3.10/−1.5
HIS 41/H-pi/3.74/−0.9
8−6.7570GLN 189/H-donor/3.31/−0.8
GLU 166/H-donor/3.00/−0.7
ASN 142/H-donor/3.37/−0.8
GLU 166/H-acceptor/2.70/−2.3
HIS 163/H-acceptor/3.02/−2.6
9−7.0953HIS 164/H-donor/3.19/−0.7
CYS 145/H-donor/3.81/−1.1
MET 165/H-donor/3.80/−0.8
MET 165/H-donor/3.57/−1.2
HIS 163/H-acceptor/3.31/−2.9
10−5.1913GLY 143/H-acceptor/2.94/−2.2
11−5.9792-
12−6.9449THR 190/H-donor/2.95/−1.7
13−5.5319-
14−5.1384GLY 143/H-acceptor/2.97/−0.4
15−6.7512PHE 140/H-donor/3.07/−0.8
CYS 145/H-donor/3.78/−1.2
HIS 163/H-acceptor/3.11/−0.7
16−6.7077GLY 143/H-acceptor/3.09/−0.7
HIS 41/H-pi/4.74/−0.6
17−5.4313-
Darunavir−6.4501GLN 189/H-donor/3.16/−2.2
ASN 142/H-donor/3.15/−0.9
GLU 166/H-acceptor/3.01/−4.0
ASN 142/pi-H/4.01/−1.6
GLY 143/pi-H/4.18/−0.6
N3−8.4847GLN 189/H-donor/2.88/−3.4
CYS 145/H-donor/3.99/−1.5
GLU 166/H-acceptor/3.08/−2.6
Table
Table 6. Physicochemical parameters and ADME of isolated ceramides, compounds 1–17, hesperidin, darunavir and N3.
Table 6. Physicochemical parameters and ADME of isolated ceramides, compounds 1–17, hesperidin, darunavir and N3.
CompoundTPSA
Å2		Log Po/w (MLOGP)GI AbsorptionBBB
Permeant		PAINS
Alert
Cer-189.794.98LowNo0
Cer-269.565.61LowNo0
Cer-3110.024.71LowNo0
Cer-4110.024.67LowNo0
Cer-5110.023.88LowNo0
Cer-6110.023.99LowNo0
137.303.81HighYes0
254.373.59HighYes0
337.304.29HighYes0
437.304.75HighNo0
537.304.38HighYes0
637.304.67HighNo0
766.763.18HighYes0
8145.910.89LowNo0
9145.910.48LowNo0
1057.534.72HighYes0
1120.236.33LowNo0
1299.383.85HighNo0
1332.765.80LowNo0
1440.465.7LowNo0
1543.703.44HighYes0
16110.023.99LowNo0
1720.233.56LowNo0
Hesperidin234.29−3.04LowNo0
Darunavir148.801.18LowNo0
N3197.830.38LowNo0
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Eltamany, E.E.; Elhady, S.S.; Goda, M.S.; Aly, O.M.; Habib, E.S.; Ibrahim, A.K.; Hassanean, H.A.; Abdelmohsen, U.R.; Safo, M.K.; Ahmed, S.A. Chemical Composition of the Red Sea Green Algae Ulva lactuca: Isolation and In Silico Studies of New Anti-COVID-19 Ceramides. Metabolites 2021, 11, 816. https://doi.org/10.3390/metabo11120816

AMA Style

Eltamany EE, Elhady SS, Goda MS, Aly OM, Habib ES, Ibrahim AK, Hassanean HA, Abdelmohsen UR, Safo MK, Ahmed SA. Chemical Composition of the Red Sea Green Algae Ulva lactuca: Isolation and In Silico Studies of New Anti-COVID-19 Ceramides. Metabolites. 2021; 11(12):816. https://doi.org/10.3390/metabo11120816

Chicago/Turabian Style

Eltamany, Enas E., Sameh S. Elhady, Marwa S. Goda, Omar M. Aly, Eman S. Habib, Amany K. Ibrahim, Hashim A. Hassanean, Usama Ramadan Abdelmohsen, Martin K. Safo, and Safwat A. Ahmed. 2021. "Chemical Composition of the Red Sea Green Algae Ulva lactuca: Isolation and In Silico Studies of New Anti-COVID-19 Ceramides" Metabolites 11, no. 12: 816. https://doi.org/10.3390/metabo11120816

APA Style

Eltamany, E. E., Elhady, S. S., Goda, M. S., Aly, O. M., Habib, E. S., Ibrahim, A. K., Hassanean, H. A., Abdelmohsen, U. R., Safo, M. K., & Ahmed, S. A. (2021). Chemical Composition of the Red Sea Green Algae Ulva lactuca: Isolation and In Silico Studies of New Anti-COVID-19 Ceramides. Metabolites, 11(12), 816. https://doi.org/10.3390/metabo11120816

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop